The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 April 2026•

1 min read

Protagonist Opts Out of Takeda Profit-Sharing Deal for $475 Million in Payments

Key Facts

1Protagonist Therapeutics exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement with Takeda.

2The company is eligible for $200 million upon election and another $200 million upon FDA approval of rusfertide.

Protagonist Therapeutics has officially exercised its right to opt out of a 50:50 U.S. profit and loss sharing arrangement with Takeda for the drug rusfertide. Under the revised terms, Protagonist is set to receive an immediate payment of $200 million, with an additional $200 million contingent upon FDA approval of the treatment. The total potential cash payments related to this opt-out and subsequent milestones reach $475 million, excluding tiered worldwide royalties. This strategic shift transitions the company from a profit-sharing model to a milestone and royalty-based compensation structure. Analysts view this move as bullish, as it provides a significant non-dilutive cash influx for the mid-cap biotech firm. The agreement effectively de-risks Protagonist's operational profile while validating the commercial potential of its polycythemia vera treatment.